Management of men with lower urinary tract symptoms referred for prostate radiotherapy

Abstract

Objective:

To report on the experience of the management of lower urinary tract symptoms (LUTS) in men referred for prostate radiotherapy (RT) in a large tertiary referral centre.

Methods:

Between February and November 2018, 156 men referred for radiotherapy were seen and assessed according to their LUTS history: International Prostate Symptom Score (IPSS), flow rate (FR) and post-void residual (PVR). Patients with LUTS were offered management options depending on severity including lifestyle advice, oral medication or surgery. A subset of patients (n = 102) were reassessed post-RT, and univariate and multivariate logistic regression was performed to predict symptoms improvement.

Results:

Prior to referral for RT and assessment at our dedicated LUTS clinic, 65% of men had a documented history of LUTS, 14% had completed an IPSS questionnaire and only 13% had a urinary FR; 17% (27/156) had prior treatment in the form of medication or surgery. In our assessment, 77/156 (49%) had mild, 66/156 (42%) moderate and 13/156 (8%) severe LUTS determined by IPSS. Out of 156, 71 (46%) had a quality-of-life score >3. Of the men, 81% were offered lifestyle advice, 47 patients were started on alpha blockers and 20 (12.8%) went onto Transurethral Resection of the Prostate prior to RT; 6 weeks following RT, 61 (50%) patients had higher IPSS scores. Patients who were started on alpha blockers (p = 0.022) or had TURP (p = 0.015) were less likely to have an increase in IPSS score on multivariate analysis.

Conclusion:

Men undergoing RT for prostate cancer often have co-existing LUTS. Consideration and evaluation of their LUTS and offer of treatment either medication or surgery could improve urinary symptoms in men undergoing prostate radiotherapy in the short term. Longer term data are still needed to understand the full long-term impact on patient’s symptoms and quality of life. We recommend that patients have formal LUTS assessment pre-RT.

Level of evidence:

Not applicable.

Keywords

Prostate cancer radiotherapy LUTS flow rate IPSS alpha blocker

Get full access to this article

View all access options for this article.

References

Manohar

CMS

Nagabhushana

Karthikeyan

, et al. Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – A double-blind randomized trial. Cent Eur J Urol 2017; 70: 148–153.

Collin

Metcalfe

Donovan

, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: A case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int 2008; 102(10): 1400–1406.

Murray

Tree

Alexander

, et al. Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: Efficacy and toxicity in the DELINEATE trial. Int J Radiat Oncol Biol Phys 2020; 106: 715–724.

Monninkhof

van Loon

JWL

van Vulpen

, et al. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial. Radiother Oncol 2018; 127(1): 74–80.

Mendez

Loblaw

Chung

, et al. Estimating acute urinary retention risk post prostate high dose-rate (HDR) brachytherapy: A clinical-based recursive partitioning analysis. Radiother Oncol 2021; 154: 118–122.

Liu

Pickles

Berthelet

, et al. Urinary incontinence in prostate cancer patients treated with external beam radiotherapy. Radiother Oncol 2005; 74(2): 197–201.

Marks

Carroll

Dugan

, et al. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31: 1257–1280.

Lee

Schultheiss

Hanlon

, et al. Urinary incontinence following external-beam radiotherapy for clinically localized prostate cancer. Urology 1996; 48(1): 95–99.

Kollmeier

Stock

Cesaretti

, et al. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 2005; 173(3): 808–812.

10.

D’Silva

Dahm

Wong

CL.

Does this man with lower urinary tract symptoms have bladder outlet obstruction? The rational clinical examination: A systematic review. JAMA 2014; 312: 535–542.

11.

Gratzke

Bachmann

Descazeaud

, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015; 67: 1099–1109.

12.

Siroky

Olsson

Krane

. The flow rate nomogram: I. Development. J Urol 1979; 122: 665–668.

13.

Reynard

Yang

Donovan

, et al. The ICS-‘BPH’ Study: Uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998; 82(5): 619–623.

14.

Yap

Brown

Cromwell

, et al. The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures. BJU Int 2009; 104(8): 1104–1108.

15.

Brown

Yap

Cromwell

, et al. Self management for men with lower urinary tract symptoms: Randomised controlled trial. BMJ 2006; 334: 25–28.

16.

Jønler

Nielsen

Wolf

Urinary symptoms, potency, and quality of life in patients with localized prostate cancer followed up with deferred treatment. Urology 1998; 52(6): 1055–1062.

17.

Polland

Vertosick

Sjoberg

, et al. Preoperative symptoms predict continence after post-radiation transurethral resection of prostate. Can J Urol 2017; 24(4): 8903–8909.

18.

Dearnaley

Syndikus

Mossop

, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17(8): 1047–1060.

19.

Yikilmaz

Öztürk

Hizli

, et al. Effect of hormonal therapy for volume reduction, lower urinary tract symptom relief and voiding symptoms in prostate cancer: Leuprolide vs goserelin. Urol J 2019; 16: 157–161.

20.

McNeill

Hargreave

Roehrborn

, et al. Alfuzosin 10 mg once daily in the management of acute urinary retention: Results of a double-blind placebo-controlled study. Urology 2005; 65(1): 83–89.

21.

Lucas

Stephenson

Nargund

Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 2005; 95: 354–357.

22.

Shah

Palit

Biyani

, et al. Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. Eur Urol 2002; 42(4): 329–332.

23.

Abrams

Griffiths

DJ.

The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 1979; 51(2): 129–134.

24.

Zelefsky

Whitmore

Leibel

, et al. Impact of transurethral resection on the long-term outcome of patients with prostatic carcinoma. J Urol 1993; 150: 1860–1864.

25.

Nakamura

Monti

Castilho

, et al. Prognostic factors for late urinary toxicity grade 2-3 after conformal radiation therapy on patients with prostate cancer. Int Braz J Urol 2007; 33(5): 652–659.

26.

Madersbacher

Marberger

Is transurethral resection of the prostate still justified?

BJU Int 1999; 83(3): 227–237.

27.

Ishiyama

Hirayama

Jhaveri

, et al. Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review. Am J Clin Oncol 2014; 37(3): 297–304.

28.

Hirshberg

Klotz

LH.

Post transurethral resection of prostate incontinence in previously radiated prostate cancer patients. Can J Urol 1998; 5(2): 560–563.

29.

Petraki

Sfikas

CP.

Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol 2007; 22(1): 107–118.

30.

Ahyai

Lehrich

Kuntz

RM.

Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial. Eur Urol 2007; 52: 1456–1464.

31.

Montorsi

Naspro

Salonia

, et al. Holmium laser enucleation versus transurethral resection of the prostate: Results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol 2004; 172: 1926–1929.

32.

Wilson

Gilling

Williams

, et al. A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: Results at 2 years. Eur Urol 2006; 50(3): 569–573.

33.

Green

Westwood

Somani

BK.

What’s new in Rezum: A transurethral water vapour therapy for BPH. Curr Urol Rep 2019; 20(7): 39.

34.

Chughtai

Thomas

Pooled aquablation results for American men with lower urinary tract symptoms due to benign prostatic hyperplasia in large prostates (60-150 cc). Adv Ther 2018; 35(6): 832–838.

35.

Jindal

Sinha

Mukherjee

, et al. Misinterpretation of the international prostate symptom score questionnaire by Indian patients. Indian J Urol 2014; 30(3): 252–255.